Anaptysbio (ANAB) Preferred Stock Liabilities (2016)
Anaptysbio's (ANAB) quarterly Preferred Stock Liabilities came in at $28.2 million in Q4 2016.
Analysis
Anaptysbio (ANAB) Preferred Stock Liabilities (2016) Analysis & Trends
Anaptysbio (ANAB) has 1 years of Preferred Stock Liabilities data on file, last reported at $28.2 million in Q4 2016.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $28.2 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $28.2 million (changed N/A YoY) and the FY2016 annual result came in at $28.2 million, changed N/A from the prior year.
- Preferred Stock Liabilities held at $28.2 million in Q4 2016.
- In the past five years, Preferred Stock Liabilities ranged from a high of $28.2 million in Q4 2016 to a low of $28.2 million in Q4 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Anaptysbio | 1.62 Bn | 1.34 Bn | - | - |